Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use.
作者信息
Crawford Melissa, van Wyk Jean, Aboud Michael, Vannappagari Vani, Romach Beth, Curtis Lloyd, Wynne Brian, de Ruiter Annemiek, Smith Kimberly, Payvandi Nassrin
机构信息
GlaxoSmithKline, Stockley Park, United Kingdom.
ViiV Healthcare, Brentford, United Kingdom; and.
出版信息
J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):e2-e5. doi: 10.1097/QAI.0000000000002213.
Abstract
摘要
相似文献
1
Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use.多替拉韦使用的妊娠结局上市后监测
J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):e2-e5. doi: 10.1097/QAI.0000000000002213.
2
The promise of paediatric dolutegravir.儿科多替拉韦的前景。
J Int AIDS Soc. 2021 Jan;24(1):e25660. doi: 10.1002/jia2.25660.
3
Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.宫内暴露于基于多替拉韦或依非韦伦的抗逆转录病毒治疗后的胎儿生物测量学
AIDS. 2020 Dec 1;34(15):2336-2337. doi: 10.1097/QAD.0000000000002674.
4
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.博茨瓦纳的神经管缺陷和抗逆转录病毒治疗方案。
N Engl J Med. 2019 Aug 29;381(9):827-840. doi: 10.1056/NEJMoa1905230. Epub 2019 Jul 22.
5
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.阿巴卡韦/多替拉韦/拉米夫定单片复方制剂：在人类免疫缺陷病毒 1 型感染中的应用评价。
Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6.
6
Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.整合酶抑制剂艾维雷格和多替拉韦在 HIV 感染孕妇中的药代动力学和安全性。
Ann Pharmacother. 2019 Aug;53(8):833-844. doi: 10.1177/1060028019830788. Epub 2019 Feb 10.
7
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.受孕时使用多替拉韦治疗导致的神经管缺陷。
N Engl J Med. 2018 Sep 6;379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24.
8
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.多替拉韦在 HIV 感染孕妇及产后妇女中的药代动力学。
AIDS. 2018 Mar 27;32(6):729-737. doi: 10.1097/QAD.0000000000001755.
9
Low-cost urine tenofovir assay to triage dolutegravir resistance testing.用于分诊多替拉韦耐药性检测的低成本尿液替诺福韦检测法。
Lancet HIV. 2024 May;11(5):e282-e283. doi: 10.1016/S2352-3018(24)00060-2. Epub 2024 Mar 7.
10
[Dolutegravir in acute HIV-1 infection: first reported case].[多替拉韦用于急性HIV-1感染：首例报告病例]
Rev Esp Quimioter. 2019 Aug;32(4):387-389. Epub 2019 Jul 11.
引用本文的文献
1
Effect of in vitro exposure of first-line antiretrovirals on healthy human spermatozoa on kinematics and motility.一线抗逆转录病毒药物体外暴露对健康人类精子运动学和活力的影响。
Int Urol Nephrol. 2025 Jun;57(6):1715-1735. doi: 10.1007/s11255-024-04340-x. Epub 2025 Jan 3.
2
Congenital malformations and preeclampsia associated with integrase inhibitor use in pregnancy: A single-center analysis.妊娠期使用整合酶抑制剂与先天畸形和子痫前期的关系：一项单中心分析。
PLoS One. 2023 Jun 12;18(6):e0276473. doi: 10.1371/journal.pone.0276473. eCollection 2023.
3
Maternal and neonatal data collection systems in low- and middle-income countries for maternal vaccines active safety surveillance systems: A scoping review.中低收入国家孕产妇和新生儿数据收集系统在孕产妇疫苗主动安全性监测系统中的应用：系统评价。
BMC Pregnancy Childbirth. 2021 Mar 17;21(1):217. doi: 10.1186/s12884-021-03686-9.
4
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.当产前抗逆转录病毒治疗在分娩前不到8周开始时，围产期强化抗逆转录病毒治疗以预防产时HIV传播。
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):313-322. doi: 10.1097/QAI.0000000000002350.
本文引用的文献
1
Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.孕期暴露于度鲁特韦后妊娠及新生儿结局。
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):371-378. doi: 10.1097/QAI.0000000000002035.
2
Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.多替拉韦和依非韦伦方案对有生育潜力的南非 HIV 感染妇女的风险与获益：一项建模研究。
Ann Intern Med. 2019 May 7;170(9):614-625. doi: 10.7326/M18-3358. Epub 2019 Apr 2.
3
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.受孕时使用多替拉韦治疗导致的神经管缺陷。
N Engl J Med. 2018 Sep 6;379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24.
4
HIV treatment in pregnancy.HIV 治疗与妊娠。
Lancet HIV. 2018 Aug;5(8):e457-e467. doi: 10.1016/S2352-3018(18)30059-6. Epub 2018 Jun 26.
5
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.博茨瓦纳开展的一项观察性研究：在孕期开始使用多替拉韦或依非韦伦为基础的抗逆转录病毒治疗的安全性比较。
Lancet Glob Health. 2018 Jul;6(7):e804-e810. doi: 10.1016/S2214-109X(18)30218-3. Epub 2018 Jun 4.
6
Practice Bulletin No. 187: Neural Tube Defects.实践公告第 187 号：神经管缺陷。
Obstet Gynecol. 2017 Dec;130(6):e279-e290. doi: 10.1097/AOG.0000000000002412.
7
Describing the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review.描述全球神经管缺陷的患病率：一项系统文献综述。
PLoS One. 2016 Apr 11;11(4):e0151586. doi: 10.1371/journal.pone.0151586. eCollection 2016.
8
Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis.与母婴 HIV 感染相关的围产期结局：系统评价和荟萃分析。
Lancet HIV. 2016 Jan;3(1):e33-48. doi: 10.1016/S2352-3018(15)00207-6. Epub 2015 Nov 27.
9
Genetic, epigenetic, and environmental contributions to neural tube closure.遗传、表观遗传和环境因素对神经管闭合的影响。
Annu Rev Genet. 2014;48:583-611. doi: 10.1146/annurev-genet-120213-092208. Epub 2014 Oct 6.
10
Neural tube defects.神经管缺陷
Annu Rev Neurosci. 2014;37:221-42. doi: 10.1146/annurev-neuro-062012-170354.
Zotero 插件